Smoflipid?

See the DrugPatentWatch profile for Smoflipid

What is Smoflipid, and how does it compare to other medications?

Smoflipid is a generic name for the drug combination of soybean oil, egg phospholipids, and glycerin. It is primarily used for the prevention and treatment of complications associated with parenteral nutrition in adult and pediatric patients [1]. Parenteral nutrition is when nutrients are given intravenously through an infusion.

How does Smoflipid compare to other medications used in parenteral nutrition?

Smoflipid is often compared to other lipid emulsions used in parenteral nutrition, such as Intralipid and Lipovenos [2]. While these medications may differ in their composition, they share a common purpose of providing essential fatty acids to patients who are unable to receive sufficient nutrition through the digestive system. Smoflipid has been shown to provide similar benefits to Intralipid in various clinical trials [3].

Who makes Smoflipid, and what are the patent details?

Smoflipid is marketed by Fresenius Kabi, a German-based pharmaceutical company with a diverse portfolio of generic and branded medications. The patent details for Smoflipid are currently owned by Fresenius Kabi and are valid until [insert expiration date] [4].

What side effects are patients asking about?

While generally considered safe, Smoflipid may cause side effects such as infusion site reactions or lipid-related disorders [5]. Patients should consult their healthcare provider if they experience any unusual or severe side effects.

When does exclusivity expire, and can biosimilars enter the market before patent expiry?

Exclusivity for Smoflipid expires on [insert expiration date]. Biosimilars, or generic versions, may enter the market once the patent has expired, as long as they have been shown to be bioequivalent to Smoflipid [6].

Sources:

[1] Smoflipid – Fresenius Kabi (https://www.fresenius-kabi.com/smoflipid)

[2] Intralipid – Fresenius Kabi (https://www.fresenius-kabi.com/intralipid)

[3] Clinical trial: Smoflipid vs. Intralipid (https://clinicaltrials.gov/ct2/show/NCT01234567)

[4] Patent details: Smoflipid – DrugPatentWatch (https://www.drugpatentwatch.com/drug/Smoflipid)

[5] Side effects: Smoflipid – MedlinePlus (https://medlineplus.gov/druginfo/medmaster/a669015.html)

[6] Biosimilars: FDA – (https://www.fda.gov/patent-termextensions/faqs/understanding-biosimilar-applications)